Kailera Therapeutics Raises $625M in IPO, Largest Biotech Offering Since 2021

Gate News message, April 17 — Kailera Therapeutics Inc. (KLRA.US), a clinical-stage biotech company focused on obesity treatment, successfully raised $625 million through its IPO today, marking the largest U.S. biotech IPO since 2021. The Waltham, Massachusetts-based company priced its offering at $16 per share, above the previously announced range of $14 to $16, selling approximately 39 million shares. The IPO was oversubscribed with double-digit demand.

Based on the offering price and shares outstanding listed in the prospectus, Kailera has a market capitalization of approximately $2 billion. The previous record for largest biotech IPO since 2021 was held by Sana Biotechnology Inc. (SANA.US), which raised $676 million in 2021. Kailera, founded in 2024, is developing four GLP-1 (glucagon-like peptide-1) based obesity medications, including a weekly injection and a daily oral tablet, both currently in late-stage clinical trials. The company competes in an increasingly crowded market, with Eli Lilly (LLY.US) and Novo Nordisk (NVO.US) leading with FDA-approved obesity drugs.

Existing shareholders, including Bain Capital Private Equity, Bain Capital Life Sciences, and the Qatar Investment Authority, committed to purchasing up to $225 million of stock at the IPO price. Bain Capital affiliates will hold approximately one-third of the company post-offering. Kailera reported a net loss of $149 million for the year ended December 2025, and a net loss of $219.7 million from its May 2024 founding through December 2024. The company is led by CEO Ronald Renaud, who previously served as CEO of Cerevel Therapeutics before its $8.7 billion acquisition by AbbVie (ABBV.US) in 2024. Kailera raised $600 million in Series B funding in October 2025, led by Bain Capital Private Equity. The stock will begin trading on the Nasdaq Global Market under the ticker “KLRA” on April 17.